生物科技公司 Aptamer Group 报告称其收入下降 50% 至 85 万英镑，但仍对 2024 年中期与联合利华合作在个人护理产品中去除异味感到乐观。 Biotech firm Aptamer Group reports 50% revenue drop to £850k, remains optimistic about Unilever partnership for malodour treatment in personal care products by mid-2024.
Aptamer Group 是一家开发 Optimer 结合剂的生物科技公司，该公司报告称，截至 2022 年 6 月的财年，其年收入下降了 50%，至 85 万英镑。 Aptamer Group, a biotech firm developing Optimer binders, reported a 50% drop in annual revenue to £850k for the financial year ending June 2022. 尽管如此，该公司对与联合利华的持续合作持乐观态度，目标是到 2024 年中期对 Optimer 粘合剂在个人护理产品恶臭处理中的人体功能研究进行研究。 Despite this, the company is optimistic about its ongoing work with Unilever, targeting on-person functionality studies for Optimer binders in malodour treatment in personal care products by mid-2024. Aptamer 与联合利华的合作始于 2022 年，目标是在两年内完成项目。 Aptamer's partnership with Unilever began in 2022, aiming for project completion within two years.